An approved rheumatoid arthritis drug developed and sold by Sanofi could become a new treatment for aggressive cancers.
The news came in a Mount Sinai press release announcing that researchers have discovered that a rheumatoid arthritis drug can block a metabolic pathway that occurs in tumors with a common cancer-causing gene mutation. The discovery offers a new possible therapy for aggressive cancers with few therapeutic options, according to a study to be published in Cancer Discovery.

Ramon Parsons, MD, PhD, Ward-Coleman Chair in Cancer Research and Chair of the Department of Oncological . . .